These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16785502)

  • 1. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
    Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML
    J Immunol; 2006 Jul; 177(1):84-91. PubMed ID: 16785502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
    Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
    J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
    Brode S; Raine T; Zaccone P; Cooke A
    J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
    Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
    Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
    Onda M; Kobayashi K; Pastan I
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses.
    Walters S; Webster KE; Sutherland A; Gardam S; Groom J; Liuwantara D; Mariño E; Thaxton J; Weinberg A; Mackay F; Brink R; Sprent J; Grey ST
    J Immunol; 2009 Jan; 182(2):793-801. PubMed ID: 19124722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.
    Baba J; Watanabe S; Saida Y; Tanaka T; Miyabayashi T; Koshio J; Ichikawa K; Nozaki K; Koya T; Deguchi K; Tan C; Miura S; Tanaka H; Tanaka J; Kagamu H; Yoshizawa H; Nakata K; Narita I
    Blood; 2012 Sep; 120(12):2417-27. PubMed ID: 22806892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
    Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
    Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.
    Chaput N; Darrasse-Jèze G; Bergot AS; Cordier C; Ngo-Abdalla S; Klatzmann D; Azogui O
    J Immunol; 2007 Oct; 179(8):4969-78. PubMed ID: 17911581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.
    Weiss VL; Lee TH; Song H; Kouo TS; Black CM; Sgouros G; Jaffee EM; Armstrong TD
    PLoS One; 2012; 7(2):e31962. PubMed ID: 22359647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin.
    Asiedu CK; Goodwin KJ; Balgansuren G; Jenkins SM; Le Bas-Bernardet S; Jargal U; Neville DM; Thomas JM
    J Immunol; 2005 Dec; 175(12):8060-8. PubMed ID: 16339543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection.
    Vokaer B; Van Rompaey N; Lemaître PH; Lhommé F; Kubjak C; Benghiat FS; Iwakura Y; Petein M; Field KA; Goldman M; Le Moine A; Charbonnier LM
    J Immunol; 2010 Sep; 185(6):3417-25. PubMed ID: 20733201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Critical Role of Induced CD4+ FoxP3+ Regulatory Cells in Suppression of Interleukin-17 Production and Attenuation of Mouse Orthotopic Lung Allograft Rejection.
    Zhou W; Zhou X; Gaowa S; Meng Q; Zhan Z; Liu J; Li J; Fan H; Liu Z
    Transplantation; 2015 Jul; 99(7):1356-64. PubMed ID: 25856405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.